3-methoxytyramine has been researched along with Parkinson Disease in 11 studies
3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "Parkinson's disease is a multifactorial neurodegenerative disorder, characterized by a reduction of dopamine (DA) levels." | 1.40 | Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease. ( Conte, C; Ianni, F; Lisanti, A; Natalini, B; Sardella, R; Scorzoni, S, 2014) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is a common and effective treatment for Parkinson's disease, but dyskinesia continues to be a serious adverse effect with chronic use." | 1.31 | Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. ( Akiyama, A; Nakazato, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chtioui, H | 1 |
| Sadowski, SM | 1 |
| Winzeler, B | 1 |
| Tschopp, O | 1 |
| Grouzmann, E | 1 |
| Abid, K | 1 |
| Eisenhofer, G | 1 |
| Brown, S | 1 |
| Peitzsch, M | 1 |
| Pelzel, D | 1 |
| Lattke, P | 1 |
| Glöckner, S | 1 |
| Stell, A | 1 |
| Prejbisz, A | 1 |
| Fassnacht, M | 1 |
| Beuschlein, F | 1 |
| Januszewicz, A | 1 |
| Siegert, G | 1 |
| Reichmann, H | 1 |
| Sardella, R | 1 |
| Scorzoni, S | 1 |
| Conte, C | 1 |
| Lisanti, A | 1 |
| Ianni, F | 1 |
| Natalini, B | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Nowak, P | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Gluck, MR | 1 |
| Zeevalk, GD | 1 |
| Jiang, H | 1 |
| Jiang, Q | 1 |
| Liu, W | 1 |
| Feng, J | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Nakazato, T | 1 |
| Akiyama, A | 1 |
| Dalmaz, Y | 1 |
| Peyrin, L | 1 |
| Kish, SJ | 1 |
| Rajput, A | 1 |
| Gilbert, J | 1 |
| Rozdilsky, B | 1 |
| Chang, LJ | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
11 other studies available for 3-methoxytyramine and Parkinson Disease
| Article | Year |
|---|---|
High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Dopamine; Dopam | 2019 |
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Dopamine; Epinephrine; Female; Humans; Levodopa; Ma | 2014 |
Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebral Cortex; Chromatography, High Pressure Liquid; Chro | 2014 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Parkin suppresses the expression of monoamine oxidases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; B-Lymphocytes; Binding Sites; Cell Line, Transformed; Cell | 2006 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Dopam | 2002 |
Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
Topics: Adrenal Gland Neoplasms; Animals; Chromatography, Ion Exchange; Dogs; Dopamine; Humans; Hydrogen-Ion | 1976 |
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
Topics: Brain Chemistry; Corpus Striatum; Dopamine; Ethanolamines; gamma-Aminobutyric Acid; Glutamate Decarb | 1986 |